Improving the outcomes in children with bacterial meningitis

Current Opinion in Infectious Diseases

Volumn 22, Issue 3, 2009, Pages 250-255

  Peltola, Heikki ^a   Roine, Irmeli ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSIDAD DIEGO PORTALES   (Chile)

Author keywords

Adjuvant treatments; Bacterial meningitis; Dexamethasone; Glycerol

Indexed keywords

CEFTRIAXONE; DEXAMETHASONE; GLYCEROL; PLACEBO; ANTIINFECTIVE AGENT; IMMUNOLOGIC FACTOR;

ADJUVANT THERAPY; ADULT DISEASE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CYTOLOGY; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEATH; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS MENINGITIS; HEARING IMPAIRMENT; HUMAN; NEUROLOGICAL COMPLICATION; PLASMA OSMOLALITY; PNEUMOCOCCAL MENINGITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; BACTERIAL MENINGITIS; CHILD; HEARING LOSS; INFANT; MORTALITY; NEUROLOGIC DISEASE; PRESCHOOL CHILD; SOUTH AND CENTRAL AMERICA;

ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DEXAMETHASONE; GLYCEROL; HEARING LOSS; HUMANS; IMMUNOLOGIC FACTORS; INFANT; LATIN AMERICA; MENINGITIS, BACTERIAL; NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME;

EID: 65549105408     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328329c47a     Document Type: Review

References (28)

1. Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N Engl J Med 1988; 319:964-971.
2. van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2007:CD004405. doi: 10.1002/14651858.CD004405.pub2.
3. Molyneux EM, Walsh AL, Forsyth H, et al. Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet 2002; 360:211-218.
4. Mongelluzzo J, Mohamad Z, Ten Have TR, Shah SS. Corticosteroids and mortality in children with bacterial meningitis. JAMA 2008; 299:2048-2055.
5. Pickering LK, Baker CJ, Long SS, McMillan JA, editors. 2006 Red book: report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.
6. Siberry GK, McMillan JA. Corticosteroids for bacterial meningitis. N Engl J Med 2008; 358:1400.
7. Peltola H, Roine I, Fernández J, et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis. A prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2007; 45:1277-1286. First trial in history since the first effective antibiotics that shows statistically significant clinical improvement in an outcome (severe neurological sequelae) of childhood bacterial meningitis.
8. Kilpi T, Peltola H, Kallio MK, et al. Oral glycerol versus intravenous dexamethasone in preventing hearing impairment due to childhood bacterial meningitis. Pediatr Infect Dis J 1995; 14:270-278.
9. Roine I, Peltola H, Fernández J, et al. Influence of admission findings on death and neurological outcome from childhood bacterial meningitis. Clin Infect Dis 2008; 46:1248-1252. Although virtually all treatment studies associate the outcome of bacterial meningitis with the causative agent, this study shows that the even more important characteristic is the child's presenting condition. This cofactor should be included in all treatment studies, and especially, if different studies are compared.
10. Pelkonen T, Roine I, Monteiro L, et al. Risk factors for death and severe neurological sequelae in childhood bacterial meningitis in Sub-Saharan Africa. Clin Infect Dis 2009; 48:1107-1110.
11. Singhi S, Järvinen A, Peltola H. Increase in serum osmolality is possible mechanism for the beneficial effects of glycerol in childhood bacterial meningitis. Pediatr Infect Dis J 2008; 27:892-896. Although GLY is an osmotic diuretic, the likely mechanism explaining its salutary effects in childhood bacterial meningitis is the increase in osmolality.
12. Sankar J, Singhi P, Bansal A, et al. Role of dexamethasone and oral glycerol in reducing hearing and neurological sequelae in children with bacterial meningitis. Indian Pediatr 2007; 44:649-656.
13. Zoghbi HV, Okumura S, Fishman MA. Acute effect of glycerol on net CSF production in dogs. Neurosurgery 1985; 63:756-762.
14. Rottenberg DA, Hurwitz BJ, Posner JB. The effect of oral glycerol on intraventricular pressure in man. Neurology 1977; 27:600-608.
15. Carrol ED, Guiver M, Nkhoma S, et al. High pneumococcal DNA loads are associated with mortality in Malawian children with invasive pneumococcal disease. Pediatr Infect Dis J 2007; 26:416-422.
16. Roine I, Saukkoriipi A, Leinonen M, et al. Microbial genome count in cerebrospinal fluid compared with clinical characteristics in pneumococcal and Haemophilus influenzae type b meningitis in children. Diagn Micro Infect Dis 2009; 63:16-23. Cerebrospinal genome counts seem to have only a rather vague correlation with the outcomes of bacterial meningitis.
17. de Gans J, van de Beek D, the European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549-1556.
18. Mai NTH, Chau TTH, Thwaites G, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med 2007; 357:2431-2440.
19. Scarborough M, Gordon SB, Whitty CJM, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med 2007; 357:2441-2450.
20. Sáez-Llorens X, McCracken GH. Glycerol and bacterial meningitis [editorial commentary]. Clin Infect Dis 2007; 45:1287-1289. An unfounded emotional attack against the large trial which demonstrated significant effects of oral GLY but not of i.v. DXM.
21. Peltola H, Roine I. Glycerol and bacterial meningitis: a response to the editorial commentary by Sáez-Llorens and McCracken. Clin Infect Dis 2008; 46:1123-1124. Response to above.
22. Zysk G, Brück W, Gerber J, et al. Anti-inflammatory treatment influences neuronal apoptotic cell death in the dentate gyrus in experimental pneumococcal meningitis. J Neuropathol Exp Neurol 1996; 55:722-728.
23. Leib S, Heimgartner C, Bifrare Y-D, et al. Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats. Pediatr Res 2003; 54:353-357.
24. Coimbra RS, Loquet G, Leib SL. Limited efficacy of adjuvant therapy with dexamethasone in preventing hearing loss due to experimental pneumococcal meningitis in the infant rat. Pediatr Res 2007; 62:291-294. Animal data showing adjuvant DXM to be ineffective in pneumococcal meningitis.
25. Singhi S, Bansal A. Serum cortisol levels in children with acute bacterial and aseptic meningitis. Pediatr Crit Care Med 2006; 7:74-78.
26. Singhi S, Singhi P. Glycerol and dexamethasone in bacterial meningitis in lowincome countries: response to the editorial commentary by Sáez-Llorens and McCracken. Clin Infect Dis 2008; 47:732-733. The question of potential harm to patient from adjuvant DXM is raised in this comment.
27. Pelkonen T, Roine I, Monteiro L, et al. Acute childhood bacterial meningitis in Luanda, Angola. Scand J Infect Dis 2008; 40:859-866.
28. Pitkäranta A, Pelkonen T, de Susa e Silva MO, et al. Setting up hearing screening in meningitis children in Luanda, Angola. Int J Pediatr Otorhinolar-yngol 2007; 71:1929-1931.